Skip navigation

Examine the Impact of Advanced Therapies, Reimbursement Approaches and Right to Try on Compassionate Use

March 27-28, 2019
  • Philadelphia, PA

CBI’s Expanded Access Programs 2019 focuses on the design, development and practical implementation of Early Access Programs. The summit convenes top industry stakeholders and regulators to examine current approaches for providing investigational, pre-launch or end-of lifecycle drugs to patients for treatment purposes. A multi-stakeholder faculty addresses key issues affecting EAPs and reviews the potential impact of the evolving legislative landscape.

Definitely, a must-attend.

Director, Global Medical Services, Med Communications

Key Topics to Be Addressed:

  • Implement practical guidelines for responding to
    inquiries around Right to Try
  • Assess whether there is an opportunity to seek
    reimbursement through traditional payer channels
  • Navigate the development process of sibling
    Early Access Programs
  • Bring the patient voice into the development of
    Early Access Programs (EAPs)
  • Learn how global organizations are handling new
    legislation on patient privacy
  • Explore how crowd funding bridges Right to Try,
    stem cell and new frontiers
  • Discuss post-clinical trial access when a program
    does not meet endpoints

Previous Attendee Acclaim:

After ten years in the expanded access space, I learned something new and heard a lot from the patient’s perspective.

Associate Director, Expanded Access, TESARO

Great insights from a variety of perspectives including the patients, regulators and manufacturers, who all addressed real issues.

Vice President, AmericansourceBergen

Definitely, a must-attend.

Director, Global Medical Services, Med Communications

The conference really brings together like-minded professionals, in a non-competitive nature, sharing lessons learned, as well as wishes to see, in the Early Access framework for the
benefit of the patient and industry.

Program Manager, Ultragenyx Pharmaceutical

Expanded Access Programs 2019

Examine the Impact of Advanced Therapies, Reimbursement Approaches and Right to Try on Compassionate Use

CBI’s Expanded Access Programs 2019 focuses on the design, development and practical implementation of Early Access Programs. The summit convenes top industry stakeholders and regulators to examine current approaches for providing investigational, pre-launch or end-of lifecycle drugs to patients for treatment purposes. A multi-stakeholder faculty addresses key issues affecting EAPs and reviews the potential impact of the evolving legislative landscape.

Definitely, a must-attend.

Director, Global Medical Services, Med Communications

Key Topics to Be Addressed:

  • Implement practical guidelines for responding to
    inquiries around Right to Try
  • Assess whether there is an opportunity to seek
    reimbursement through traditional payer channels
  • Navigate the development process of sibling
    Early Access Programs
  • Bring the patient voice into the development of
    Early Access Programs (EAPs)
  • Learn how global organizations are handling new
    legislation on patient privacy
  • Explore how crowd funding bridges Right to Try,
    stem cell and new frontiers
  • Discuss post-clinical trial access when a program
    does not meet endpoints

Previous Attendee Acclaim:

After ten years in the expanded access space, I learned something new and heard a lot from the patient’s perspective.

Associate Director, Expanded Access, TESARO

Great insights from a variety of perspectives including the patients, regulators and manufacturers, who all addressed real issues.

Vice President, AmericansourceBergen

Definitely, a must-attend.

Director, Global Medical Services, Med Communications

The conference really brings together like-minded professionals, in a non-competitive nature, sharing lessons learned, as well as wishes to see, in the Early Access framework for the
benefit of the patient and industry.

Program Manager, Ultragenyx Pharmaceutical